Unlike many biotechs, Vertex has consistently cast itself as a product-focused company. To get there, Vertex built a remarkably productive discovery engine that has generated an impressive development pipeline. But to date, the company has produced only one commercial product, an HIV therapy marketed by GSK. That relatively slow path to commercialization is in large part attributable to the company's reliance on its internal R&D to produce drugs. By eschewing the in-licensing path that other biotechs have taken to jumpstart their commercial development, and partnering away commercial rights to a number of its later-stage compounds, the company has left some doubting its commitment to marketing its own drugs. But Vertex is now laying the foundation for creating a full-fledged commercial capability. And if the company can stay on track as it tackles the challenges of integrating a commercial operation into its organization, it may prove the skeptics wrong and accomplish something that perhaps no other biotech has: create a fully integrated pharmaceutical firm on the back of its own R&D.
By Jeffrey Dvorin
Joshua Boger, PhD, has never been shy about his ambitions for Vertex Pharmaceuticals Inc. , the company he founded...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.
Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.